Have a personal or library account? Click to login

Influence of the complex drug Cocarnit on the sciatic nerve in the development of diabetic polyneuropathy in rats

Open Access
|Sep 2020

References

  1. 1. Diabetes mellitus. WHO; 2010.
  2. 2. Amin N, Doupis J. Diabetic foot disease: From the evaluation of the «foot at risk» to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016;7(7):153-64.10.4239/wjd.v7.i7.153482468627076876
  3. 3. Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016;17(6):E917.10.3390/ijms17060917492645027294922
  4. 4. Tatianenko LV, Bogdanov GN, Varfolomeev VN, Kotelnikova RA, Shaposhnikova GI, Smirnov LD. Structural-functional changes in biomembranes during complications of diabetes mellitus and their pharmacological correction. Vopr Med Khim. 2017;44(6):551-8.
  5. 5. Zochodne DW. Diabetes mellitus and the peripheral nervous system: Manifestations and mechanisms. Muscle Nerve. 2007;6(2):144-66.10.1002/mus.2078517469109
  6. 6. Jack M, Wright DE. The role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res. 2012;159(5):355-65.10.1016/j.trsl.2011.12.004332921822500508
  7. 7. Grindel A, Guggenberger B, Eichberger L, Pöppelmeyer C, Gschaider M, Tosevska A, et al. Oxidative stress, DNA Damage and DNA repair in female patients with diabetes mellitus type 2. PLoS One. 2016;11(9):1-17.10.1371/journal.pone.0162082501260327598300
  8. 8. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002;16:1738-48.10.1096/fj.01-1027com12409316
  9. 9. Mehra A, Ali C, Parcq J, Vivien D, Docagne F. The plasminogen activation system in neuroinflammation. BBA - Molecular Basis of Disease. 2016;1862(3):395-402.10.1016/j.bbadis.2015.10.01126493446
  10. 10. Aisina RB, Muk hametova LI. Structure and function of plasminogen/plasmin system. Russ J Bioorg Chem. 2014;40:590-605.10.1134/S106816201406002825895360
  11. 11. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52(12):2867-73.10.2337/diabetes.52.12.286714633845
  12. 12. Taiana MM, Lombardi R, Porretta-Serapiglia C, Ciusani E, Oggioni N, Sassone J, et al. Neutralization of Sschwann cell-secreted VEGF is protective to in vitro and in vivo experimental diabetic neuropathy. Zhou R, editor. PLoS One. 2014;9(9):e108403.10.1371/journal.pone.0108403418245525268360
  13. 13. Brewster WJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci. 1994;17(8):321-5.10.1016/0166-2236(94)90169-4
  14. 14. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000;284(17):2215-21.10.1001/jama.284.17.2215
  15. 15. Chen S-Q, Cai Q, Shen Y-Y, Cai X-Y, Lei H-Y. Combined use of NGF/BDNF/bFGF promotes proliferation and differentiation of neural stem cells in vitro. Int J Dev Neurosci. 2014;38:74-8.10.1016/j.ijdevneu.2014.08.002
  16. 16. Abe K, Saito H. Effects of basic fibroblast growth factor on central nervous system functions. Pharmacol Res. 2001:43(4):307-12.10.1006/phrs.2000.0794
  17. 17. Katsuki H, Itsukaichi Y, Matsuki N. Distinct signaling pathways involved in multiple effects of basic fibroblast growth factor on cultured rat hippocampal neurons. Brain Res. 2000;885(2):240-50.10.1016/S0006-8993(00)02953-X
  18. 18. Grothe C, Nikkhah G. The role of basic fibroblast growth factor in peripheral nerve regeneration. Anat Embryol (Berl). 2001;204(3):171-7.10.1007/s00429010020511681796
  19. 19. Fujimoto E, Mizoguchi A, Hanada K, Yajima M, Ide C. Basic fibroblast growth factor promotes extension of regenerating axons of peripheral nerve. In vivo experiments using a Schwann cell basal lamina tube model. J Neurocytol. 1997;26(8):511-28.10.1023/A:1015410023132
  20. 20. Li X, Zhang J, Zhao W, Yang H, Yang H, Ma J, Qi Y, et al. Effect of Tongxinluo on nerve regeneration in mice with diabetic peripheral neuropathy. Cell Mol Biol (Noisy-le-grand). 2015;61(5):103-7.
  21. 21. Li R, Ma J, Wu Y, Nangle M, Zou S, Li Y, et al. Dual delivery of NGF and bFGF coacervater ameliorates diabetic peripheral neuropathy via inhibiting schwann cells apoptosis. Int J Biol Sci. 2017:13(5):640-51.10.7150/ijbs.18636544118028539836
  22. 22. Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15-28.10.1177/2040622314552071426961025553239
  23. 23. Schreiber AK. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes. 2015;6(3):432.10.4239/wjd.v6.i3.432439890025897354
  24. 24. Elgayar SA, Eltony SA, Sayed AA, Abbas AY. Protective effect of vitamin B complex in diabetic peripheral neuropathy. Histopathological study. Eur J Anat. 2017;21(3):173-87.
  25. 25. Kirichek LT. Pharmacology of vitamins. Int Med J. 2001;7(4):97-104.
  26. 26. 26. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, at al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst. Rev. 2008;16(3):CD004573.
  27. 27. Zhang YF, Ning G. Mecobalamin. Expert Opin Investig Drugs. 2008;17(6):953-64.10.1517/13543784.17.6.953
  28. 28. Roy RP, Ghosh K, Ghosh M, Acharyya A, Bhattacharya A, Pal M, Chakraborty S, Sengupta N. Study of Vitamin B12 deficiency and peripheral neuropathy in metformin-treated early Type 2 diabetes mellitus. Indian J Endocrinol Metab. 2016;20(5):631-7.10.4103/2230-8210.190542
  29. 29. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006;11:294-329.
  30. 30. Andrès E, Loukili NH, Noel E. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004;171:251-9.10.1503/cmaj.1031155
  31. 31. Liu KW, Dai LK, Jean W. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35:200-1.10.1093/ageing/afj042
  32. 32. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006;166:1975-9.10.1001/archinte.166.18.1975
  33. 33. Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, et al. Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol. 2010;222:191-203.10.1016/j.expneurol.2009.12.017
  34. 34. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005;14:48-54.
  35. 35. Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2): 5-9.10.11622/smedj.2016027
  36. 36. Nozdrenko D, Beregovyi S, Nikitina N, Stepanova L, Beregova T, Ostapchenko L. The influence of complex drug cocarnit on the nerve conduction velocity in nerve tibialis of rats with diabetic polyneuropathy. Biomed Res. 2018;29(19):3629-34.
  37. 37. Kotov SV, Isakova EV, Leidvoll VY, Belova YuA, Volchenkova TV, Borodin AV, et al. The efficacy of cocarnit in diabetic neuropathy. Zh Nevrol Psikhiatr Im S.S. Korsakova. 2018;118(1):37-42.10.17116/jnevro20181181137-42
  38. 38. Smelt HJM, Pouwels S, Said M, Smulders JF. Neuropathy by folic acid supplementation in a patient with anaemia and an untreated cobalamin deficiency: a case report. Clin Obes. 2018;8(4):300-4.10.1111/cob.12254
  39. 39. Gibson GE, Park LC, Sheu KF, Blass JP, Calingasan NY. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem Int. 2000;36(2):97-112.10.1016/S0197-0186(99)00114-X
  40. 40. Hoffer A. Use of nicotinic acid and/or nicotinamide in high doses to treat schizophrenia. Can J Psychiatr Nurs. 1966;7(8):5-6.
  41. 41. Belov VG, Parfenov IA, Zaplutanov VA. Features of psychopharmacotherapeutic correction of alcohol dependence in the elderly. Adv Gerontol. 2013;26(4):702-6.
  42. 42. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-94.10.1111/j.1476-5381.2012.01911.x341741522352879
  43. 43. Sarkisova DS, Perova YuL. Microscopic technique: Management. Moscow: Medicine. 1996;544.
  44. 44. Crowther JR. The ELISA guidebook. Methods Mol Biol. 2000;149: 1-413.10.1385/1592590497
  45. 45. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.10.1016/0003-2697(76)90527-3
  46. 46. Heussen C. Dowdle E. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1980;102:196-202.10.1016/0003-2697(80)90338-3
  47. 47. Ostapchenko L, Savchuk O, Burlova-Vasilieva N. Enzyme electrophoresis m ethod in analysis of active components of haemostasis system. Adv Biosci Biotechnol. 2011; 2(1):20-6.10.4236/abb.2011.21004
  48. 48. Harlow E. Lane D. Antibodies. Cold Spring Harbor Laboratory. New York; 1998: 726.
  49. 49. Protein Electrophoresis Technical manual. Amersham Biosciences Inc.; 1999.
  50. 50. Rebrova OYu. Statistical analysis of medical data. Application of application package STATISTICA. Moscow: Media Sph; 2002:312.
  51. 51. Yang X-W, Liu F-Q, Guo J-J, Yao W-J, Li Q-Q, Liu T-H, et al. Antioxidation and anti-inflammatory activity of Tang Bi Kang in rats with diabetic peripheral neuropathy. BMC Complement Altern Med. 2015;15(1):66.10.1186/s12906-015-0600-0
  52. 52. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.10.1038/414813a
  53. 53. Yakobchuk SO, Ihefody AG, Kolotylo OB. Questions of the pathogenesis of diabetic neuropathy. Bukovinsky Medical Bulletin. 2012;16(63):142-5.
  54. 54. Barlow GH, Summaria L, Robbins KC. Molecular weight studies on human plasminogen and plasmin at the microgram level. J Biol Chem. 1969;244(5):1138-41.10.1016/S0021-9258(18)91819-3
  55. 55. Graiani G, Emanueli C, Desortes E, Linthout SV, Pinna A, Figueroa CD, et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of Type 1 diabetic mice. Diabetologia. 2004;47(6):1047-54.10.1007/s00125-004-1414-715164170
  56. 56. Nozdrenko D, Berehovyi S, Nikitina N, Stepanova L,Beregova T, Ostapchenko L. The influence of complex drug cocarnit on the nerve conduction velocity in nerve tibialis of rats with diabetic polyneuropathy Biomed Res. 2018;29(19):3629-34.10.4066/biomedicalresearch.29-18-1055
  57. 57. Beregova TV, Nozdrenko DM, Beregovyi SM, Nikitina NS, Falalyeyeva TM, Ostapchenkо LI. Dynamic properties of skeletal muscle contraction in rats with diabetes. UK: St George`s Healthcare NHS Trust. 2018;7:119-39.10.5772/intechopen.70600
  58. 58. Malik RA. Pathology of human diabetic neuropathy. Clinical Neurology. 2004;249-59.10.1016/B978-0-444-53480-4.00016-325410227
  59. 59. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract. 2007;77(1): 184-89.10.1016/j.diabres.2007.01.054
  60. 60. Pittenger G, Vinik A, Pittenger GL. Nerve growth factor and diabetic neuropathy. Exp Diab Res. 2003;4:71-85.10.1155/EDR.2003.271
  61. 61. Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1996;37(7):1311-21.
  62. 62. Lindberger M, Schröder HD, Schultzberg M, Kristensson K, Persson A, Ostman J, et al. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of neuropeptides in diabetes mellitus. J Neurol Sci. 1989;93(2-3):289-96.10.1016/0022-510X(89)90198-6
  63. 63. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994;634(1):7-12.10.1016/0006-8993(94)90252-6
  64. 64. Hulse RP, Beazley-Long N, Ved N, Bestall SM, Riaz H, Singhal P, et al. Vascular endothelial growth factor-A 165 b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clin Sci. 2015;129(8):741-56.10.1042/CS20150124
  65. 65. Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K, et al. Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabet Med. 2009;26(3):247-52.10.1111/j.1464-5491.2009.02680.x
  66. 66. Imamura T, Engleka K, Zhan X, Tokita Y, Forough R, Roeder D, et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science.1990;249(4976):1567-70.10.1126/science.1699274
  67. 67. Yang HT, Yan Z, Abraham JA, Terjung RL. VEGF - and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Circ Physiol. 2001;280(3):H1097-104.10.1152/ajpheart.2001.280.3.H1097
  68. 68. Shaw R, Cianchetti R, Pleasure D, Kreider B. Basic fibroblast growth factor prevents cAMP-induced apoptosis in cultured Schwann cells. J Neurosci Res. 1997;47(4):400-4.10.1002/(SICI)1097-4547(19970215)47:4<;400::AID-JNR5>3.0.CO;2-I
  69. 69. Iwai-Kanai E, Hasegawa K, Fujita M, Araki M, Yanazume T, Adachi S, et al. Basic fibroblast growth factor protects cardiac myocytes from iNOS-mediated apoptosis. J Cell Physiol. 2002;190(1):54-62.10.1002/jcp.10036
  70. 70. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 2000;11(4):295-302.10.1016/S1359-6101(00)00014-9
  71. 71. Kawaguchi H, Kurokawa T, Hanada K, Tamura M, Ogata E, Matsumoto T. Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology. 1994;135(2):774-81.10.1210/endo.135.2.80338268033826
  72. 72. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, et al. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology. 1995;136(3):1276-84.10.1210/endo.136.3.78675827867582
  73. 73. Nakae M, Kamiya H, Naruse K, Horio N, Ito Y, Mizubayashi R, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes. 2006;55(5):1470-7.10.2337/db05-116016644707
  74. 74. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest. 1995;96(2):1159-63.10.1172/JCI1181041853077635953
  75. 75. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999;48(10):2090-5.10.2337/diabetes.48.10.209010512378
DOI: https://doi.org/10.2478/cipms-2020-0021 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 113 - 120
Submitted on: Oct 31, 2019
Accepted on: May 4, 2020
Published on: Sep 13, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Nataliia Nikitina, Serhii Berehoviy, Ludmila Stepanova, Olexiy Savchuk, Olena Kuryk, Ludmila Ostapchenko, Tetyana Beregova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.